13G Filing: Tangiers Global, Llc and Endonovo Therapeutics Inc. (ENDV)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of
1934

 

(AMENDMENT NO. ___) *

 

Endonovo Therapeutics, Inc.

(Name of issuer)

 

Common Stock. $.0001 value per share

(Title of class of securities)

29272H201

(CUSIP number)

 

March 20, 2017

(Date of Event Which Requires filing of
this Statement)

Check the appropriate box to designate
the rule pursuant to which this Schedule is filed:

¨

Rule 13d-l (b)

x

Rule 13d-l(c)

¨

Rule 13d-l(d)

* The remainder of this cover
page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the
remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).

 

Persons who respond to the collection of information
contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1745 (1-06)

CUSIP No. 29272H201

13G

Page 2 of 5 Pages

1.	Name of Reporting Person I.R.S. Identification Nos. of above persons (entities only). TANGIERS GLOBAL, LLC. EIN: 81-1631927
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Wyoming

Number of Shares Beneficially Owned by Reporting Person With:	5.	Sole Voting Power 19,059,779*
	6.	Shared Voting Power
	7.	Sole Dispositive Power 19,059,779*
	8.	Shared Dispositive Power

9.	Aggregate Amount Beneficially Owned by Each Reporting Person 19,059,779*
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
11. 9.99%*	Percent of Class Represented by Amount in Row (9)
12. CO	Type of Reporting Person (See Instructions)

FOOTNOTES

*Tangiers has rights, under a Convertible Promissory Note,
to own an aggregate number of shares of the Issuer’s common stock, which, except for a contractual cap on the amount of
outstanding shares of the Issuer’s common stock that Tangiers may own, could exceed such a cap. Tangiers’s ownership
cap is 9.99%. Thus, the number of shares of the Issuer’s common stock beneficially owned by Tangiers as of the date of this
filing was 19,059,779* shares, as calculated in accordance with Rule 13d-3(d)(1) under the Securities Exchange Act of 1934, which
is 9.99% of the 190,788,582 shares that were outstanding on that date.

CUSIP No. 29272H201

13G

Page 3 of 5 Pages

Item 1

(a)

Name of lssuer:

Endonovo
Therapeutics, Inc.

(b)

Address Of Issuer’s Principal Executive Offices:

6320
Canoga Avenue, 15h Floor, Woodland Hills, CA 91367

 

Item 2

(a)

Name of Person Filing:

TANGIERS GLOBAL, LLC.

(b)

Address of Principal Business Office, or, if none, Residence:

Caribe Plaza Office Building 6^th
Floor, Palmeras St. #53

San Juan, PR 00901

(c)

Citizenship:

Wyoming

(d)

Title of Class of Securities:

Common Stock, $.0001 value per
share

(e)

Cusip Number:

29272H201

 

Item 3

If this statement is filed pursuant to §240.13d-I(b) or 240.13d-2(b) or (c), check whether the person filing is a:

	(a)	¨	Broker or dealer registered under section 15 of the Act (15 U.S.C, 78o).
	(b)	¨	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)	¨	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)	¨	Investment company registered under section 8 of the Investment Company Act (15 U.S.C.80a-8).
	(e)	¨	An investment adviser in accordance with §240.13d-l(b)(l)(ii)(E).
	(f)	¨	An employee benefit plan or endowment fund in accordance with §240.13d-l(b)(ii)(F).
	(g)	¨	A parent holding company or control person in accordance with §240.13d-l(b)(l)(ii)(G).
	(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813).
	(i)	¨	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)	¨	Group in accordance with §240.13d-l(b)(ii)(J).

CUSIP No. 29272H201

13G

Page 4 of 5 Pages

Item 4

Ownership

(a)

Amount beneficially owned 19,059,779*

(b)

Percent of class: 9.99%*

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote 19,059,779*

(ii)

Shared power to vote or to direct the vote

(iii)

Sole power to dispose or to direct the disposition of 19,059,779*

(iv)

Shared power to dispose or to direct the disposition of

*Tangiers has rights, under a Convertible Promissory Note,
to own an aggregate number of shares of the Issuer’s common stock, which, except for a contractual cap on the amount of
outstanding shares of the Issuer’s common stock that Tangiers may own, could exceed such a cap. Tangiers’s ownership
cap is 9.99%. Thus, the number of shares of the Issuer’s common stock beneficially owned by Tangiers as of the date of this
filing was 19,059,779* shares, as calculated in accordance with Rule 13d-3(d)(1) under the Securities Exchange Act of 1934, which
is 9.99% of the 190,788,582 shares that were outstanding on that date.

 

Item 5

Ownership of Five Percent or Less of a Class

If this
statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner
of more than five percent of the class of securities, check the following ¨

 

Item 6

Ownership of More Than Five Percent on Behalf Of Another Person

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

 

Item 8

Identification and Classification of Members of The Group

 

Item 9

Notice of Dissolution of Group

 

Item 10

Certification

(a)

The following certification shall be included if the statement is filed pursuant to §240.13d-l (b):

By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held
in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant
in any transaction having that purpose or effect.

(b)

The following certification shall be included if the statement is filed pursuant to §240.13d-l(c):

By
signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 29272H201

13G

Page 5 of 5 Pages

SIGNATURE

 

After reasonable
inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.

	March 20, 2017
	Date
	/s/ Michael Sobeck
	Signature
	Michael Sobeck, Managing Member
	Name/Title

The original statement shall be signed
by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of
a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of
the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that
a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and
any title of each person who signs the statement shall be typed or printed beneath his signature.

 

NOTE : Schedules filed in paper format shall include
a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom
copies are to be sent.

 

Attention: Intentional misstatements
or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)